• Health2Sync, Asia's leading chronic disease management platform, has secured over $20 million in a Series C funding round, paving the way for a planned public listing on the Taiwan capital markets.
• This capital will fuel strategic growth as Health2Sync prepares for its IPO: expanding into new markets (Japan, South Korea, Australia), developing new disease management programs (weight loss, hypertension, GLP-1), and deepening AI integration.
• This investment reflects strong investor confidence in Health2Sync's established market leadership, its vision to transform chronic disease management through data-driven solutions, and its strategic path towards a public listing.

TAIPEI, TAIWAN - Media OutReach Newswire - 5 March 2025 - Health2Sync (H2), a leading digital health company specializing in chronic disease management, today announced it has raised over US$20 million in a Series C funding round and earlier extension round. This investment will propel the company's growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan.